Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G, Calvez V. Marcelin AG, et al. Among authors: costagliola d. J Med Virol. 2004 Sep;74(1):16-20. doi: 10.1002/jmv.20140. J Med Virol. 2004. PMID: 15258963
Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.
Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F, Costagliola D. Katlama C, et al. Among authors: costagliola d. Ann Intern Med. 1998 Oct 1;129(7):525-31. doi: 10.7326/0003-4819-129-7-199810010-00003. Ann Intern Med. 1998. PMID: 9758571
Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.
Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D. Salmon-Céron D, et al. Among authors: costagliola d. AIDS. 2000 May 26;14(8):1041-9. doi: 10.1097/00002030-200005260-00017. AIDS. 2000. PMID: 10853987 Clinical Trial.
Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study.
Descamps D, Calvez V, Izopet J, Buffet-Janvresse C, Schmuck A, Colson P, Ruffault A, Maillard A, Masquelier B, Cottalorda J, Harzic M, Brun-Vézinet F, Costagliola D; ANRS Antiretroviral Resistance Study Group. Descamps D, et al. Among authors: costagliola d. AIDS. 2001 Sep 28;15(14):1777-82. doi: 10.1097/00002030-200109280-00005. AIDS. 2001. PMID: 11579238
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy.
Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Châtelet FP, Katlama C, Charlotte F, Dupont B, Brousse N, Huerre M, Mikol J, Camparo P, Mokhtari K, Tulliez M, Salmon-Céron D, Boué F, Costagliola D, Raphaël M. Besson C, et al. Among authors: costagliola d. Blood. 2001 Oct 15;98(8):2339-44. doi: 10.1182/blood.v98.8.2339. Blood. 2001. PMID: 11588028 Free article.
Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy.
Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vezinet F, Calvez V. Mouroux M, et al. Among authors: costagliola d. Antivir Ther. 2001 Sep;6(3):179-83. Antivir Ther. 2001. PMID: 11808752
731 results